Colon Cancer, Esophageal Cancer, Gastric Polyp, Hypoxia
Conditions
Keywords
the COMBO Endoscopy Oropharyngeal Airway, Hypoxia, Gastrointestinal Endoscopy, Propofol, Sedation
Brief summary
Hypoxia represents the prevailing adverse occurrence during the sedation of patients undergoing gastrointestinal endoscopy with propofol. A recent innovation in this domain is the COMBO Endoscopy Oropharyngeal Airway-a multifaceted device that encompasses capnography monitoring, bite block , oxygenation support, and oropharyngeal airway management. This device has been purposefully designed to cater to the unique requirements of endoscopic procedures. The principal objective of our randomized study is to assess the efficacy and safety of the COMBO Endoscopy Oropharyngeal Airway reduce the incidence of hypoxia on patients undergoing gastrointestinal endoscopy under propofol sedation.
Interventions
Using the COMBO Endoscopy Oropharyngeal Airway for oxygenation.
DEVICERegular Nasal Cannula
Using regular nasal cannula for oxygenation.
Sponsors
RenJi Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Age 18≤ Age ≤60. * Patients undergoing gastroendoscopy and/or colonoscopy procedure. * Patients have signed the informed consent form. * The ASA classification ranges from I to II. * The estimated duration of the procedure does not exceed 45 minutes.
Exclusion criteria
* Patients who exhibit contraindications to oropharyngeal airway ventilation, such as coagulation disorders, a predisposition to oral and nasal bleeding, mucosal damage, or anatomical constraints impeding oropharyngeal channel placement. * Severe cardiac insufficiency, defined as a maximal exercise capacity of less than 4 metabolic equivalents (METs). * Profound renal insufficiency necessitating preoperative dialysis. * A confirmed severe liver dysfunction. * Patients diagnosed with chronic obstructive pulmonary disease (COPD) or those presently experiencing other acute and chronic pulmonary conditions necessitating prolonged or intermittent oxygen therapy. * Elevated intracranial pressure. * Upper respiratory tract infections, encompassing the oral, nasal, and pharyngeal regions. * Fever, defined as a core body temperature exceeding 37.5 degrees Celsius. * Pregnancy or lactation. * Hypersensitivity reactions to sedatives like propofol or medical equipment such as adhesive tape. * Urgent surgical intervention. * Polytrauma. * Peripheral oxygen saturation (SpO2) levels below 95% while breathing room air preoperatively. * BMI\<18.5 or BMI\>30. * Patients with a documented history of substance abuse, specifically drugs and/or alcohol, within the two years preceding the commencement of the screening period. Substance abuse in this context is defined as consuming more than three standard alcoholic beverages daily, roughly equivalent to 10g of alcohol or 50g of Chinese Baijiu. * Patients with a history of mental and neurological disorders, including but not limited to depression, severe central nervous system depression, Parkinson's disease, basal ganglia lesions, schizophrenia, epilepsy, Alzheimer's disease, and myasthenia gravis. * Presently engaged in concurrent participation in additional clinical trials. * Patients considered ineligible by researchers for inclusion in this clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of hypoxia | Patients will be followed for the duration of hospital stay, an expected average about 2 hours | (75% ≤ SpO2 \< 90% for \<60 s) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of sub-clinical respiratory depression | Patients will be followed for the duration of hospital stay, an expected average about 2 hours | (90% ≤ SpO2 \< 95%) |
| The incidence of severe hypoxia | Patients will be followed for the duration of hospital stay, an expected average about 2 hours | (SpO2 \< 75% or 75% ≤ SpO2 \< 90% for ≥60 s) |
Other
| Measure | Time frame | Description |
|---|---|---|
| The incidence of other adverse events | Patients will be followed for the duration of hospital stay, an expected average about 2 hours | Other adverse events recorded by tools proposed by the World Society of Intravenous Anesthesia International Sedation Task Force |
Countries
China
Contacts
Primary ContactDiansan Su, Dr.
Backup ContactYuhan Zhang, B.S
Outcome results
None listed